Eterna Therapeutics Inc.(ERNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ERNA Eterna Therapeutics Inc.

Not Yet Opened 11-03 16:00:00 EST

2.02

+0.07

+3.59%

盘后2.02

+0.000.00%

19:20 EST

High2.12	Low1.99	Vol11.37K
Open2.08	D1 Closing1.95	Amplitude6.84%
Mkt Cap3.30M	Tradable Cap2.49M	Total Shares1.63M
T/O23.05K	T/O Rate0.92%	Tradable Shares1.23M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ERNA","market":"US","secType":"STK","nameCN":"Eterna Therapeutics Inc.","latestPrice":2.02,"timestamp":1793739600000,"preClose":1.95,"halted":0,"volume":11373,"hourTrading":{"tag":"盘后","latestPrice":2.02,"preClose":2.02,"latestTime":"19:20 EST","volume":757,"amount":1530.3,"timestamp":1793751603085,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.03589743589743593,"floatShares":1232213,"shares":1632400,"eps":-18.605883,"marketStatus":"Not Yet Opened","change":0.07,"latestTime":"11-03 16:00:00 EST","open":2.075,"high":2.1234,"low":1.99,"amount":23045.5784676,"amplitude":0.06841,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-18.605883,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1793782800000},"marketStatusCode":0,"adr":0,"listingDate":465451200000,"exchange":"NASDAQ","adjPreClose":1.95,"preHourTrading":{"tag":"盘前","latestPrice":2.1223,"preClose":1.95,"latestTime":"08:55 EST","volume":16,"amount":34.0945008,"timestamp":1793714110719,"change":0.1723,"changeRate":0.088359,"amplitude":0.009077},"postHourTrading":{"tag":"盘后","latestPrice":2.02,"preClose":2.02,"latestTime":"19:20 EST","volume":757,"amount":1530.3,"timestamp":1793751603085,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.790516},"requestUrl":"/m/hq/s/ERNA/wiki","defaultTab":"wiki","newsList":[{"id":"2675077948","title":"Ernexa Therapeutics Joins Virtual Investor Closing Bell Series Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2675077948","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675077948?lang=en_us&edition=fundamental","pubTime":"2026-10-13 04:06","pubTimestamp":1791835562,"startTime":"0","endTime":"0","summary":"Ernexa Therapeutics joins Virtual Investor Closing Bell Series webcastErnexa Therapeutics will join the Virtual Investor Closing Bell Series on Oct. 15, 2026 at 4:00 p.m. ET.Management plans a corpora","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261012:nNDL7GDL6F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","BK4585","BK4139","NDAQ","IE00BGHQF748.EUR","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014013.SGD","SG9999014021.USD","BK4112","IE00BN0W2T93.GBP","LU2210149790.SGD","IE00BKPKM429.USD","IE00BN0W2W23.USD","BK4588","LU2210150020.SGD","ERNA","IE00BQXX3D17.EUR","IE00BN0W2V16.EUR","LU2095319765.USD","SG9999014005.SGD","IE00BQXX3F31.USD","BCDF","IE00BQXX3C00.GBP","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673592820","title":"Ernexa Says ERNA-101 Preclinical Data Win Flash Talk Slot at Nature-MD Anderson Cancer Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2673592820","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673592820?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:55","pubTimestamp":1791291323,"startTime":"0","endTime":"0","summary":"Ernexa says ERNA-101 preclinical data win flash talk slot at Nature-MD Anderson cancer meetingErnexa Therapeutics disclosed new preclinical results for ERNA-101, selected for a Flash Talk at a Nature ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nNDLbPj55b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BQXX3D17.EUR","LU2210149790.SGD","IE00B64PRP62.GBP","SG9999014005.SGD","SG9999014039.USD","ERNA","IE00BKPKM429.USD","BK4112","IE00BN0W2V16.EUR","LU0314104364.USD","LU2095319765.USD","BK4585","SG9999014013.SGD","IE00BN0W2W23.USD","IE00BQXX3C00.GBP","NDAQ","SG9999014021.USD","BCDF","IE00BQXX3F31.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","BK4588","IE00B3QW5Z07.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672075089","title":"Ernexa Therapeutics Appoints Robert J. Spiegel to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2672075089","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672075089?lang=en_us&edition=fundamental","pubTime":"2026-10-01 21:20","pubTimestamp":1790860818,"startTime":"0","endTime":"0","summary":"Ernexa Therapeutics appoints Robert J. Spiegel to board of directorsErnexa Therapeutics appointed Robert J. Spiegel to its board as it sharpens its oncology focus and advances ERNA-101.Spiegel spent m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDL9fbjBG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3C00.GBP","SG9999014005.SGD","SG9999014013.SGD","BCDF","IE00B64PRP62.GBP","IE00BKPKM429.USD","IE00BN0W2V16.EUR","LU2210150020.SGD","IE00BQXX3F31.USD","IE00BN0W2W23.USD","BK4585","IE00BGHQF748.EUR","LU2095319765.USD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","LU2210149790.SGD","BK4139","IE00BQXX3D17.EUR","SG9999014021.USD","SG9999014039.USD","LU0314104364.USD","BK4112","NDAQ","BK4588","ERNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672975086","title":"Ernexa Therapeutics CEO Corner Highlights Appointment of DR. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances Erna-101 Toward the Clinic","url":"https://stock-news.laohu8.com/highlight/detail?id=2672975086","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672975086?lang=en_us&edition=fundamental","pubTime":"2026-10-01 21:20","pubTimestamp":1790860800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nTUAP94LW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672975037","title":"Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic","url":"https://stock-news.laohu8.com/highlight/detail?id=2672975037","media":"GlobeNewswire","labels":["executive","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672975037?lang=en_us&edition=fundamental","pubTime":"2026-10-01 21:20","pubTimestamp":1790860800,"startTime":"0","endTime":"0","summary":"CEO Discusses How Addition of Accomplished Oncology Drug Developer Strengthens Ernexa Ahead of Clinical Development Following ERNA-101 Data Demonstrating Complete Tumor Clearance and 100% Survival in ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/01/3373011/0/en/ernexa-therapeutics-ceo-corner-highlights-appointment-of-dr-robert-j-spiegel-as-company-sharpens-oncology-focus-and-advances-erna-101-toward-the-clinic.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ERNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671410202","title":"Ernexa Therapeutics announces ‘highly encouraging’ results on ERNA-101","url":"https://stock-news.laohu8.com/highlight/detail?id=2671410202","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671410202?lang=en_us&edition=fundamental","pubTime":"2026-09-30 20:50","pubTimestamp":1790772642,"startTime":"0","endTime":"0","summary":"Ernexa Therapeutics (ERNA) announced “highly encouraging” results from three core Investigational New Drug-enabling safety studies of ERNA-101, its...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ernexa-therapeutics-announces-highly-encouraging-results-on-erna-101-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ernexa-therapeutics-announces-highly-encouraging-results-on-erna-101-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ERNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671204182","title":"Ernexa Targets Q4 2026 IND Filing for First-in-Human ERNA-101 Trial in Platinum-Resistant Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2671204182","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671204182?lang=en_us&edition=fundamental","pubTime":"2026-09-30 20:32","pubTimestamp":1790771578,"startTime":"0","endTime":"0","summary":"Ernexa targets Q4 2026 IND filing for first-in-human ERNA-101 trial in platinum-resistant ovarian cancerErnexa reported new preclinical safety results for ERNA-101, supporting a planned IND filing in ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nNDL4C9J7t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4112","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","IE00BQXX3C00.GBP","IE00BGHQF748.EUR","LU0314104364.USD","NDAQ","LU2210150020.SGD","BK4588","ERNA","IE00BN0W2W23.USD","IE00BQXX3F31.USD","IE00BQXX3D17.EUR","BK4585","SG9999014021.USD","IE00BKPKM429.USD","IE00BN0W2V16.EUR","SG9999014013.SGD","LU2210149790.SGD","BK4139","LU2095319765.USD","SG9999014005.SGD","BCDF","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671920497","title":"Ernexa Therapeutics - no Teratoma Formation Observed in Erna-101-Treated Animals Through Six-Month Tumorigenicity Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2671920497","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671920497?lang=en_us&edition=fundamental","pubTime":"2026-09-30 20:32","pubTimestamp":1790771520,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nTUA43TD6M:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ERNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671204978","title":"Ernexa Therapeutics Reports Compelling Erna-101 Safety Results Across Three Critical Ind-Enabling Studies, Advancing Toward Planned Q4 2026 Ind","url":"https://stock-news.laohu8.com/highlight/detail?id=2671204978","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671204978?lang=en_us&edition=fundamental","pubTime":"2026-09-30 20:32","pubTimestamp":1790771520,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nTUA43TD6M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671204920","title":"Ernexa Therapeutics - Biodistribution Study Shows no Significant Erna-101 Signal in Tumor-Free Animals or Non-Tumor Tissues","url":"https://stock-news.laohu8.com/highlight/detail?id=2671204920","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671204920?lang=en_us&edition=fundamental","pubTime":"2026-09-30 20:32","pubTimestamp":1790771520,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nTUA43TD6M:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671049272","title":"Ernexa Therapeutics - Repeat-Dose Glp Toxicology Study Shows no Erna-101-Related Adverse Findings","url":"https://stock-news.laohu8.com/highlight/detail?id=2671049272","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671049272?lang=en_us&edition=fundamental","pubTime":"2026-09-30 20:32","pubTimestamp":1790771520,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nTUA43TD6M:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ERNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671202674","title":"Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND","url":"https://stock-news.laohu8.com/highlight/detail?id=2671202674","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671202674?lang=en_us&edition=fundamental","pubTime":"2026-09-30 20:32","pubTimestamp":1790771520,"startTime":"0","endTime":"0","summary":"Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no clinical pathology or histopathology findings; single-dose assessment showed no","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/30/3371881/0/en/ernexa-therapeutics-reports-compelling-erna-101-safety-results-across-three-critical-ind-enabling-studies-advancing-toward-planned-q4-2026-ind.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","BK4139","ERNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671277217","title":"Ernexa Therapeutics selected for Emerging Track at 2026 Cell, Gene meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2671277217","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671277217?lang=en_us&edition=fundamental","pubTime":"2026-09-29 21:36","pubTimestamp":1790688963,"startTime":"0","endTime":"0","summary":"Ernexa Therapeutics (ERNA) announced that the Company has been selected for the Emerging Track at the 2026 Cell & Gene Meeting on the Mesa, taking ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ernexa-therapeutics-selected-for-emerging-track-at-2026-cell-gene-meeting-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ernexa-therapeutics-selected-for-emerging-track-at-2026-cell-gene-meeting-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ERNA","BK4139","LENZ","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671421788","title":"Ernexa Therapeutics CEO to Present at Cell & Gene Meeting on the Mesa Emerging Track","url":"https://stock-news.laohu8.com/highlight/detail?id=2671421788","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671421788?lang=en_us&edition=fundamental","pubTime":"2026-09-29 21:15","pubTimestamp":1790687729,"startTime":"0","endTime":"0","summary":"Ernexa Therapeutics CEO to present at Cell & Gene Meeting on the Mesa Emerging TrackErnexa will present at the 2026 Cell & Gene Meeting on the Mesa in Mesa, Arizona, held Oct. 5-7, 2026.CEO Sanjeev Lu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nNDL66j4CB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00BQXX3C00.GBP","BK4139","IE00BN0W2W23.USD","BK4112","ERNA","BCDF","IE00B3QW5Z07.USD","NDAQ","IE00BN0W2V16.EUR","SG9999014005.SGD","LU2210150020.SGD","LU0314104364.USD","SG9999014013.SGD","IE00BGHQF748.EUR","BK4588","LU2095319765.USD","IE00BN0W2T93.GBP","SG9999014039.USD","IE00BQXX3D17.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","IE00BQXX3F31.USD","BK4585","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669223251","title":"Ernexa Therapeutics Director Robert J. Spiegel Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2669223251","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669223251?lang=en_us&edition=fundamental","pubTime":"2026-09-23 04:13","pubTimestamp":1790108033,"startTime":"0","endTime":"0","summary":"Ernexa Therapeutics director Robert J. Spiegel files initial beneficial ownership statementDirector Robert J. Spiegel filed an initial Form 3 at Ernexa Therapeutics, disclosing his insider status as o","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL7Lqq4s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ERNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668497935","title":"Ernexa Therapeutics Appoints Robert J. Spiegel to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2668497935","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668497935?lang=en_us&edition=fundamental","pubTime":"2026-09-17 04:51","pubTimestamp":1789591885,"startTime":"0","endTime":"0","summary":"Ernexa Therapeutics appoints Robert J. Spiegel to board of directorsErnexa Therapeutics appointed Robert J. Spiegel, M.D., to its board, effective Sept. 14, 2026.Spiegel will serve until a successor i","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nNDL6B98FZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ERNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667647881","title":"Ernexa Therapeutics - Intends to Broaden Oncology Program and Advance Next-Generation Imsc Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2667647881","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667647881?lang=en_us&edition=fundamental","pubTime":"2026-09-15 20:42","pubTimestamp":1789476120,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nTUA1VC3LQ:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667642078","title":"Ernexa Therapeutics - to Concentrate Near-Term Resources on Erna-101 and Broaden Oncology Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2667642078","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667642078?lang=en_us&edition=fundamental","pubTime":"2026-09-15 20:42","pubTimestamp":1789476120,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nTUA1VC3LQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ERNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667642073","title":"Ernexa Therapeutics Reports Positive Disease Modifying Erna-201 Preclinical Data, Reinforcing Imsc Platform as Company Accelerates Oncology Strategy and Erna-101 Toward First-in-Human Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2667642073","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667642073?lang=en_us&edition=fundamental","pubTime":"2026-09-15 20:42","pubTimestamp":1789476120,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nTUA1VC3LQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667642029","title":"Ernexa Therapeutics - to Advance Erna-101 Toward Ind Submission for Platinum-Resistant Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2667642029","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667642029?lang=en_us&edition=fundamental","pubTime":"2026-09-15 20:42","pubTimestamp":1789476120,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nTUA1VC3LQ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ernexatx.com","stockEarnings":[{"period":"1week","weight":0.0135},{"period":"1month","weight":-0.3176},{"period":"3month","weight":-0.5073},{"period":"6month","weight":-0.7417},{"period":"1year","weight":-0.9516},{"period":"ytd","weight":-0.9327}],"compareEarnings":[{"period":"1week","weight":-0.0199},{"period":"1month","weight":-0.0199},{"period":"3month","weight":-0.0201},{"period":"6month","weight":0.0311},{"period":"1year","weight":0.1039},{"period":"ytd","weight":0.1062}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.558824,"avgChangeRate":0.130666},{"month":2,"riseRate":0.382353,"avgChangeRate":-0.039626},{"month":3,"riseRate":0.558824,"avgChangeRate":0.018953},{"month":4,"riseRate":0.352941,"avgChangeRate":0.335049},{"month":5,"riseRate":0.411765,"avgChangeRate":0.015195},{"month":6,"riseRate":0.5,"avgChangeRate":0.005635},{"month":7,"riseRate":0.257143,"avgChangeRate":-0.04689},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.016811},{"month":9,"riseRate":0.314286,"avgChangeRate":-0.035612},{"month":10,"riseRate":0.342857,"avgChangeRate":-0.051035},{"month":11,"riseRate":0.514286,"avgChangeRate":0.054174},{"month":12,"riseRate":0.323529,"avgChangeRate":-0.050712}],"exchange":"NASDAQ","name":"Eterna Therapeutics Inc.","nameEN":"Eterna Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Eterna Therapeutics Inc.(ERNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Eterna Therapeutics Inc.(ERNA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Eterna Therapeutics Inc.,ERNA,Eterna Therapeutics Inc.股票,Eterna Therapeutics Inc.股票老虎,Eterna Therapeutics Inc.股票老虎国际,Eterna Therapeutics Inc.行情,Eterna Therapeutics Inc.股票行情,Eterna Therapeutics Inc.股价,Eterna Therapeutics Inc.股市,Eterna Therapeutics Inc.股票价格,Eterna Therapeutics Inc.股票交易,Eterna Therapeutics Inc.股票购买,Eterna Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Eterna Therapeutics Inc.(ERNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Eterna Therapeutics Inc.(ERNA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction